

Global CAR T-Cell-Based Drug Supply, Demand and Key Producers, 2023-2029

https://marketpublishers.com/r/G43A172C6408EN.html

Date: March 2023

Pages: 107

Price: US\$ 4,480.00 (Single User License)

ID: G43A172C6408EN

Abstracts

The global CAR T-Cell-Based Drug market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.

This report studies the global CAR T-Cell-Based Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for CAR T-Cell-Based Drug, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of CAR T-Cell-Based Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global CAR T-Cell-Based Drug total market, 2018-2029, (USD Million)

Global CAR T-Cell-Based Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: CAR T-Cell-Based Drug total market, key domestic companies and



share, (USD Million)

Global CAR T-Cell-Based Drug revenue by player and market share 2018-2023, (USD Million)

Global CAR T-Cell-Based Drug total market by Type, CAGR, 2018-2029, (USD Million)

Global CAR T-Cell-Based Drug total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global CAR T-Cell-Based Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics, Autolus Therapeutics and Sorrento Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World CAR T-Cell-Based Drug market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global CAR T-Cell-Based Drug Market, By Region:

United States

China

Europe

Japan



South Korea
ASEAN
India
Rest of World
Global CAR T-Cell-Based Drug Market, Segmentation by Type
CD19-targeted
BCMA-targeted
Global CAR T-Cell-Based Drug Market, Segmentation by Application
Lymphoma
Multiple Myeloma
Companies Profiled:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CAR The same first

CARsgen Therapeutics



Autolus Therapeutics		
Sorrento Therapeutics		
Mustang Bio		
Bluebird Bio		
Cellectis		
Allogene Therapeutics		
Celyad		
Key Questions Answered		
1. How big is the global CAR T-Cell-Based Drug market?		
2. What is the demand of the global CAR T-Cell-Based Drug market?		
3. What is the year over year growth of the global CAR T-Cell-Based Drug market?		
4. What is the total value of the global CAR T-Cell-Based Drug market?		
5. Who are the major players in the global CAR T-Cell-Based Drug market?		
6. What are the growth factors driving the market demand?		



Contents

1 SUPPLY SUMMARY

- 1.1 CAR T-Cell-Based Drug Introduction
- 1.2 World CAR T-Cell-Based Drug Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World CAR T-Cell-Based Drug Total Market by Region (by Headquarter Location)
- 1.3.1 World CAR T-Cell-Based Drug Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States CAR T-Cell-Based Drug Market Size (2018-2029)
 - 1.3.3 China CAR T-Cell-Based Drug Market Size (2018-2029)
 - 1.3.4 Europe CAR T-Cell-Based Drug Market Size (2018-2029)
 - 1.3.5 Japan CAR T-Cell-Based Drug Market Size (2018-2029)
 - 1.3.6 South Korea CAR T-Cell-Based Drug Market Size (2018-2029)
 - 1.3.7 ASEAN CAR T-Cell-Based Drug Market Size (2018-2029)
 - 1.3.8 India CAR T-Cell-Based Drug Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 CAR T-Cell-Based Drug Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 CAR T-Cell-Based Drug Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World CAR T-Cell-Based Drug Consumption Value (2018-2029)
- 2.2 World CAR T-Cell-Based Drug Consumption Value by Region
 - 2.2.1 World CAR T-Cell-Based Drug Consumption Value by Region (2018-2023)
- 2.2.2 World CAR T-Cell-Based Drug Consumption Value Forecast by Region (2024-2029)
- 2.3 United States CAR T-Cell-Based Drug Consumption Value (2018-2029)
- 2.4 China CAR T-Cell-Based Drug Consumption Value (2018-2029)
- 2.5 Europe CAR T-Cell-Based Drug Consumption Value (2018-2029)
- 2.6 Japan CAR T-Cell-Based Drug Consumption Value (2018-2029)
- 2.7 South Korea CAR T-Cell-Based Drug Consumption Value (2018-2029)
- 2.8 ASEAN CAR T-Cell-Based Drug Consumption Value (2018-2029)
- 2.9 India CAR T-Cell-Based Drug Consumption Value (2018-2029)



3 WORLD CAR T-CELL-BASED DRUG COMPANIES COMPETITIVE ANALYSIS

- 3.1 World CAR T-Cell-Based Drug Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global CAR T-Cell-Based Drug Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for CAR T-Cell-Based Drug in 2022
- 3.2.3 Global Concentration Ratios (CR8) for CAR T-Cell-Based Drug in 2022
- 3.3 CAR T-Cell-Based Drug Company Evaluation Quadrant
- 3.4 CAR T-Cell-Based Drug Market: Overall Company Footprint Analysis
 - 3.4.1 CAR T-Cell-Based Drug Market: Region Footprint
 - 3.4.2 CAR T-Cell-Based Drug Market: Company Product Type Footprint
 - 3.4.3 CAR T-Cell-Based Drug Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: CAR T-Cell-Based Drug Revenue Comparison (by Headquarter Location)
- 4.1.1 United States VS China: CAR T-Cell-Based Drug Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
- 4.1.2 United States VS China: CAR T-Cell-Based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: CAR T-Cell-Based Drug Consumption Value Comparison
- 4.2.1 United States VS China: CAR T-Cell-Based Drug Consumption Value Comparison (2018 & 2022 & 2029)
- 4.2.2 United States VS China: CAR T-Cell-Based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based CAR T-Cell-Based Drug Companies and Market Share, 2018-2023
- 4.3.1 United States Based CAR T-Cell-Based Drug Companies, Headquarters (States, Country)
- 4.3.2 United States Based Companies CAR T-Cell-Based Drug Revenue, (2018-2023)
- 4.4 China Based Companies CAR T-Cell-Based Drug Revenue and Market Share,



2018-2023

- 4.4.1 China Based CAR T-Cell-Based Drug Companies, Company Headquarters (Province, Country)
- 4.4.2 China Based Companies CAR T-Cell-Based Drug Revenue, (2018-2023)
- 4.5 Rest of World Based CAR T-Cell-Based Drug Companies and Market Share, 2018-2023
- 4.5.1 Rest of World Based CAR T-Cell-Based Drug Companies, Headquarters (States, Country)
- 4.5.2 Rest of World Based Companies CAR T-Cell-Based Drug Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

- 5.1 World CAR T-Cell-Based Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
- 5.2 Segment Introduction by Type
 - 5.2.1 CD19-targeted
 - 5.2.2 BCMA-targeted
- 5.3 Market Segment by Type
 - 5.3.1 World CAR T-Cell-Based Drug Market Size by Type (2018-2023)
 - 5.3.2 World CAR T-Cell-Based Drug Market Size by Type (2024-2029)
 - 5.3.3 World CAR T-Cell-Based Drug Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

- 6.1 World CAR T-Cell-Based Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
- 6.2 Segment Introduction by Application
 - 6.2.1 Lymphoma
 - 6.2.2 Multiple Myeloma
- 6.3 Market Segment by Application
 - 6.3.1 World CAR T-Cell-Based Drug Market Size by Application (2018-2023)
 - 6.3.2 World CAR T-Cell-Based Drug Market Size by Application (2024-2029)
 - 6.3.3 World CAR T-Cell-Based Drug Market Size by Application (2018-2029)

7 COMPANY PROFILES

- 7.1 Novartis
 - 7.1.1 Novartis Details
 - 7.1.2 Novartis Major Business



- 7.1.3 Novartis CAR T-Cell-Based Drug Product and Services
- 7.1.4 Novartis CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
- 7.1.5 Novartis Recent Developments/Updates
- 7.1.6 Novartis Competitive Strengths & Weaknesses
- 7.2 Gilead Sciences
 - 7.2.1 Gilead Sciences Details
 - 7.2.2 Gilead Sciences Major Business
 - 7.2.3 Gilead Sciences CAR T-Cell-Based Drug Product and Services
- 7.2.4 Gilead Sciences CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.2.5 Gilead Sciences Recent Developments/Updates
 - 7.2.6 Gilead Sciences Competitive Strengths & Weaknesses
- 7.3 Bristol-Myers Squibb
 - 7.3.1 Bristol-Myers Squibb Details
 - 7.3.2 Bristol-Myers Squibb Major Business
 - 7.3.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Product and Services
- 7.3.4 Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.3.5 Bristol-Myers Squibb Recent Developments/Updates
 - 7.3.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
- 7.4 J & J
 - 7.4.1 J & J Details
 - 7.4.2 J & J Major Business
 - 7.4.3 J & J CAR T-Cell-Based Drug Product and Services
- 7.4.4 J & J CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.4.5 J & J Recent Developments/Updates
- 7.4.6 J & J Competitive Strengths & Weaknesses
- 7.5 JW Therapeutics
 - 7.5.1 JW Therapeutics Details
 - 7.5.2 JW Therapeutics Major Business
 - 7.5.3 JW Therapeutics CAR T-Cell-Based Drug Product and Services
- 7.5.4 JW Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.5.5 JW Therapeutics Recent Developments/Updates
 - 7.5.6 JW Therapeutics Competitive Strengths & Weaknesses
- 7.6 FOSUNKite
- 7.6.1 FOSUNKite Details



- 7.6.2 FOSUNKite Major Business
- 7.6.3 FOSUNKite CAR T-Cell-Based Drug Product and Services
- 7.6.4 FOSUNKite CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.6.5 FOSUNKite Recent Developments/Updates
 - 7.6.6 FOSUNKite Competitive Strengths & Weaknesses
- 7.7 CARsgen Therapeutics
 - 7.7.1 CARsgen Therapeutics Details
 - 7.7.2 CARsgen Therapeutics Major Business
 - 7.7.3 CARsgen Therapeutics CAR T-Cell-Based Drug Product and Services
- 7.7.4 CARsgen Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.7.5 CARsgen Therapeutics Recent Developments/Updates
 - 7.7.6 CARsgen Therapeutics Competitive Strengths & Weaknesses
- 7.8 Autolus Therapeutics
 - 7.8.1 Autolus Therapeutics Details
 - 7.8.2 Autolus Therapeutics Major Business
 - 7.8.3 Autolus Therapeutics CAR T-Cell-Based Drug Product and Services
- 7.8.4 Autolus Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.8.5 Autolus Therapeutics Recent Developments/Updates
 - 7.8.6 Autolus Therapeutics Competitive Strengths & Weaknesses
- 7.9 Sorrento Therapeutics
 - 7.9.1 Sorrento Therapeutics Details
 - 7.9.2 Sorrento Therapeutics Major Business
 - 7.9.3 Sorrento Therapeutics CAR T-Cell-Based Drug Product and Services
- 7.9.4 Sorrento Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.9.5 Sorrento Therapeutics Recent Developments/Updates
 - 7.9.6 Sorrento Therapeutics Competitive Strengths & Weaknesses
- 7.10 Mustang Bio
 - 7.10.1 Mustang Bio Details
 - 7.10.2 Mustang Bio Major Business
 - 7.10.3 Mustang Bio CAR T-Cell-Based Drug Product and Services
- 7.10.4 Mustang Bio CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.10.5 Mustang Bio Recent Developments/Updates
- 7.10.6 Mustang Bio Competitive Strengths & Weaknesses
- 7.11 Bluebird Bio



- 7.11.1 Bluebird Bio Details
- 7.11.2 Bluebird Bio Major Business
- 7.11.3 Bluebird Bio CAR T-Cell-Based Drug Product and Services
- 7.11.4 Bluebird Bio CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.11.5 Bluebird Bio Recent Developments/Updates
 - 7.11.6 Bluebird Bio Competitive Strengths & Weaknesses
- 7.12 Cellectis
 - 7.12.1 Cellectis Details
 - 7.12.2 Cellectis Major Business
 - 7.12.3 Cellectis CAR T-Cell-Based Drug Product and Services
- 7.12.4 Cellectis CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.12.5 Cellectis Recent Developments/Updates
- 7.12.6 Cellectis Competitive Strengths & Weaknesses
- 7.13 Allogene Therapeutics
 - 7.13.1 Allogene Therapeutics Details
 - 7.13.2 Allogene Therapeutics Major Business
 - 7.13.3 Allogene Therapeutics CAR T-Cell-Based Drug Product and Services
- 7.13.4 Allogene Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.13.5 Allogene Therapeutics Recent Developments/Updates
 - 7.13.6 Allogene Therapeutics Competitive Strengths & Weaknesses
- 7.14 Celyad
 - 7.14.1 Celyad Details
 - 7.14.2 Celyad Major Business
 - 7.14.3 Celyad CAR T-Cell-Based Drug Product and Services
- 7.14.4 Celyad CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023)
 - 7.14.5 Celyad Recent Developments/Updates
- 7.14.6 Celyad Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 CAR T-Cell-Based Drug Industry Chain
- 8.2 CAR T-Cell-Based Drug Upstream Analysis
- 8.3 CAR T-Cell-Based Drug Midstream Analysis
- 8.4 CAR T-Cell-Based Drug Downstream Analysis



9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer



List Of Tables

LIST OF TABLES

Table 1. World CAR T-Cell-Based Drug Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World CAR T-Cell-Based Drug Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World CAR T-Cell-Based Drug Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World CAR T-Cell-Based Drug Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World CAR T-Cell-Based Drug Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World CAR T-Cell-Based Drug Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World CAR T-Cell-Based Drug Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World CAR T-Cell-Based Drug Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World CAR T-Cell-Based Drug Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key CAR T-Cell-Based Drug Players in 2022

Table 12. World CAR T-Cell-Based Drug Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global CAR T-Cell-Based Drug Company Evaluation Quadrant

Table 14. Head Office of Key CAR T-Cell-Based Drug Player

Table 15. CAR T-Cell-Based Drug Market: Company Product Type Footprint

Table 16. CAR T-Cell-Based Drug Market: Company Product Application Footprint

Table 17. CAR T-Cell-Based Drug Mergers & Acquisitions Activity

Table 18. United States VS China CAR T-Cell-Based Drug Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China CAR T-Cell-Based Drug Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based CAR T-Cell-Based Drug Companies, Headquarters (States, Country)

Table 21. United States Based Companies CAR T-Cell-Based Drug Revenue, (2018-2023) & (USD Million)



- Table 22. United States Based Companies CAR T-Cell-Based Drug Revenue Market Share (2018-2023)
- Table 23. China Based CAR T-Cell-Based Drug Companies, Headquarters (Province, Country)
- Table 24. China Based Companies CAR T-Cell-Based Drug Revenue, (2018-2023) & (USD Million)
- Table 25. China Based Companies CAR T-Cell-Based Drug Revenue Market Share (2018-2023)
- Table 26. Rest of World Based CAR T-Cell-Based Drug Companies, Headquarters (States, Country)
- Table 27. Rest of World Based Companies CAR T-Cell-Based Drug Revenue, (2018-2023) & (USD Million)
- Table 28. Rest of World Based Companies CAR T-Cell-Based Drug Revenue Market Share (2018-2023)
- Table 29. World CAR T-Cell-Based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029
- Table 30. World CAR T-Cell-Based Drug Market Size by Type (2018-2023) & (USD Million)
- Table 31. World CAR T-Cell-Based Drug Market Size by Type (2024-2029) & (USD Million)
- Table 32. World CAR T-Cell-Based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029
- Table 33. World CAR T-Cell-Based Drug Market Size by Application (2018-2023) & (USD Million)
- Table 34. World CAR T-Cell-Based Drug Market Size by Application (2024-2029) & (USD Million)
- Table 35. Novartis Basic Information, Area Served and Competitors
- Table 36. Novartis Major Business
- Table 37. Novartis CAR T-Cell-Based Drug Product and Services
- Table 38. Novartis CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 39. Novartis Recent Developments/Updates
- Table 40. Novartis Competitive Strengths & Weaknesses
- Table 41. Gilead Sciences Basic Information, Area Served and Competitors
- Table 42. Gilead Sciences Major Business
- Table 43. Gilead Sciences CAR T-Cell-Based Drug Product and Services
- Table 44. Gilead Sciences CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 45. Gilead Sciences Recent Developments/Updates



- Table 46. Gilead Sciences Competitive Strengths & Weaknesses
- Table 47. Bristol-Myers Squibb Basic Information, Area Served and Competitors
- Table 48. Bristol-Myers Squibb Major Business
- Table 49. Bristol-Myers Squibb CAR T-Cell-Based Drug Product and Services
- Table 50. Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue, Gross Margin and
- Market Share (2018-2023) & (USD Million)
- Table 51. Bristol-Myers Squibb Recent Developments/Updates
- Table 52. Bristol-Myers Squibb Competitive Strengths & Weaknesses
- Table 53. J & J Basic Information, Area Served and Competitors
- Table 54. J & J Major Business
- Table 55. J & J CAR T-Cell-Based Drug Product and Services
- Table 56. J & J CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 57. J & J Recent Developments/Updates
- Table 58. J & J Competitive Strengths & Weaknesses
- Table 59. JW Therapeutics Basic Information, Area Served and Competitors
- Table 60. JW Therapeutics Major Business
- Table 61. JW Therapeutics CAR T-Cell-Based Drug Product and Services
- Table 62. JW Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and
- Market Share (2018-2023) & (USD Million)
- Table 63. JW Therapeutics Recent Developments/Updates
- Table 64. JW Therapeutics Competitive Strengths & Weaknesses
- Table 65. FOSUNKite Basic Information, Area Served and Competitors
- Table 66. FOSUNKite Major Business
- Table 67. FOSUNKite CAR T-Cell-Based Drug Product and Services
- Table 68. FOSUNKite CAR T-Cell-Based Drug Revenue, Gross Margin and Market
- Share (2018-2023) & (USD Million)
- Table 69. FOSUNKite Recent Developments/Updates
- Table 70. FOSUNKite Competitive Strengths & Weaknesses
- Table 71. CARsgen Therapeutics Basic Information, Area Served and Competitors
- Table 72. CARsgen Therapeutics Major Business
- Table 73. CARsgen Therapeutics CAR T-Cell-Based Drug Product and Services
- Table 74. CARsgen Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 75. CARsgen Therapeutics Recent Developments/Updates
- Table 76. CARsgen Therapeutics Competitive Strengths & Weaknesses
- Table 77. Autolus Therapeutics Basic Information, Area Served and Competitors
- Table 78. Autolus Therapeutics Major Business
- Table 79. Autolus Therapeutics CAR T-Cell-Based Drug Product and Services



- Table 80. Autolus Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. Autolus Therapeutics Recent Developments/Updates
- Table 82. Autolus Therapeutics Competitive Strengths & Weaknesses
- Table 83. Sorrento Therapeutics Basic Information, Area Served and Competitors
- Table 84. Sorrento Therapeutics Major Business
- Table 85. Sorrento Therapeutics CAR T-Cell-Based Drug Product and Services
- Table 86. Sorrento Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. Sorrento Therapeutics Recent Developments/Updates
- Table 88. Sorrento Therapeutics Competitive Strengths & Weaknesses
- Table 89. Mustang Bio Basic Information, Area Served and Competitors
- Table 90. Mustang Bio Major Business
- Table 91. Mustang Bio CAR T-Cell-Based Drug Product and Services
- Table 92. Mustang Bio CAR T-Cell-Based Drug Revenue, Gross Margin and Market
- Share (2018-2023) & (USD Million)
- Table 93. Mustang Bio Recent Developments/Updates
- Table 94. Mustang Bio Competitive Strengths & Weaknesses
- Table 95. Bluebird Bio Basic Information, Area Served and Competitors
- Table 96. Bluebird Bio Major Business
- Table 97. Bluebird Bio CAR T-Cell-Based Drug Product and Services
- Table 98. Bluebird Bio CAR T-Cell-Based Drug Revenue, Gross Margin and Market
- Share (2018-2023) & (USD Million)
- Table 99. Bluebird Bio Recent Developments/Updates
- Table 100. Bluebird Bio Competitive Strengths & Weaknesses
- Table 101. Cellectis Basic Information, Area Served and Competitors
- Table 102. Cellectis Major Business
- Table 103. Cellectis CAR T-Cell-Based Drug Product and Services
- Table 104. Cellectis CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 105. Cellectis Recent Developments/Updates
- Table 106. Cellectis Competitive Strengths & Weaknesses
- Table 107. Allogene Therapeutics Basic Information, Area Served and Competitors
- Table 108. Allogene Therapeutics Major Business
- Table 109. Allogene Therapeutics CAR T-Cell-Based Drug Product and Services
- Table 110. Allogene Therapeutics CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 111. Allogene Therapeutics Recent Developments/Updates
- Table 112. Celyad Basic Information, Area Served and Competitors



- Table 113. Celyad Major Business
- Table 114. Celyad CAR T-Cell-Based Drug Product and Services
- Table 115. Celyad CAR T-Cell-Based Drug Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 116. Global Key Players of CAR T-Cell-Based Drug Upstream (Raw Materials)
- Table 117. CAR T-Cell-Based Drug Typical Customers



List Of Figures

LIST OF FIGURES

Figure 1. CAR T-Cell-Based Drug Picture

Figure 2. World CAR T-Cell-Based Drug Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World CAR T-Cell-Based Drug Total Market Size (2018-2029) & (USD Million)

Figure 4. World CAR T-Cell-Based Drug Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Figure 5. World CAR T-Cell-Based Drug Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company CAR T-Cell-Based Drug Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company CAR T-Cell-Based Drug Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company CAR T-Cell-Based Drug Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company CAR T-Cell-Based Drug Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company CAR T-Cell-Based Drug Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company CAR T-Cell-Based Drug Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company CAR T-Cell-Based Drug Revenue (2018-2029) & (USD Million)

Figure 13. CAR T-Cell-Based Drug Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World CAR T-Cell-Based Drug Consumption Value (2018-2029) & (USD Million)

Figure 16. World CAR T-Cell-Based Drug Consumption Value Market Share by Region (2018-2029)

Figure 17. United States CAR T-Cell-Based Drug Consumption Value (2018-2029) & (USD Million)

Figure 18. China CAR T-Cell-Based Drug Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe CAR T-Cell-Based Drug Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan CAR T-Cell-Based Drug Consumption Value (2018-2029) & (USD



Million)

Figure 21. South Korea CAR T-Cell-Based Drug Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN CAR T-Cell-Based Drug Consumption Value (2018-2029) & (USD Million)

Figure 23. India CAR T-Cell-Based Drug Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of CAR T-Cell-Based Drug by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for CAR T-Cell-Based Drug Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for CAR T-Cell-Based Drug Markets in 2022

Figure 27. United States VS China: CAR T-Cell-Based Drug Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: CAR T-Cell-Based Drug Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World CAR T-Cell-Based Drug Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World CAR T-Cell-Based Drug Market Size Market Share by Type in 2022

Figure 31. CD19-targeted

Figure 32. BCMA-targeted

Figure 33. World CAR T-Cell-Based Drug Market Size Market Share by Type (2018-2029)

Figure 34. World CAR T-Cell-Based Drug Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 35. World CAR T-Cell-Based Drug Market Size Market Share by Application in 2022

Figure 36. Lymphoma

Figure 37. Multiple Myeloma

Figure 38. CAR T-Cell-Based Drug Industrial Chain

Figure 39. Methodology

Figure 40. Research Process and Data Source



I would like to order

Product name: Global CAR T-Cell-Based Drug Supply, Demand and Key Producers, 2023-2029

Product link: https://marketpublishers.com/r/G43A172C6408EN.html

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G43A172C6408EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970